期刊文献+

14例唑来膦酸不良反应文献分析 被引量:7

Literature Analysis of 14 Cases of Adverse Drug Reactions Induced by Zoledronic Acid
下载PDF
导出
摘要 目的:分析唑来膦酸不良反应发生的规律及特点,为合理用药提供参考。方法:检索唑来膦酸在中国上市以来中国学术期刊全文数据库(CNKI)、维普中文科技期刊数据库(VIP)收载的不良反应文献进行统计分析。结果:唑来膦酸不良反应的个案报道共14例,男性3例,女性11例,年龄最小为43岁,最大为78岁,年龄50岁以上发生率较高(11例,78.6%);不良反应分别涉及全身性损害、肌肉骨骼系统损害、代谢和营养障碍、肝胆系统损害等。结论:临床医师和药师应了解唑来膦酸致不良反应的规律和特点,加强用药监测,以减少不良反应的发生。 Objective:To analyze the general rules and characteristics of the adverse drug reactions(ADRs)induced by zoledronic acid so as to provide a reference for rational drug use in clinical practice.Methods:ADRs of zoledronic acid were retrieved from CNKI and VIP database since it was put into market in China and the data was analyzed statistically. Results:Totally 14 cases of ADRs(including 3 men and 11 women)caused by zoledronic acid were collected. The youngest patient was 43 years old and the oldest was 78 years old. The patients over the age of 50 showed the highest incidence(n= 11,78.6%). Their ADRs were involved in systemic damage such as musculo-skeletal system damage, metabolic and nutritional disorders, and hepatobiliary system damage,etc.Conclusion:Clinicians and pharmacists should understand the rules and characteristics of the ADRs induced by zoledronic acid and strengthen monitoring on drug use so as to reduce the incidence of ADR.
作者 韩一萱
出处 《中国执业药师》 CAS 2014年第8期3-6,共4页 China Licensed Pharmacist
关键词 唑来膦酸 不良反应 文献分析 Zoledronic Acid Adverse Reactions Literature Analysis
  • 相关文献

参考文献7

二级参考文献43

  • 1厉有名.药物性肝损害的临床类型及诊断策略[J].中华肝脏病杂志,2004,12(7):445-446. 被引量:252
  • 2彭六保,崔巍.唑来膦酸的临床应用研究进展[J].中国新药与临床杂志,2007,26(3):237-240. 被引量:36
  • 3BONNEL RA, BUSSE GD. Zolendronic acid (marketed as reclast) : renal impairment and acute renal failure[ J]. Drug Safety Newsletter, 2009,2(2) : 26-27.
  • 4ROSEN ES, GORDEN D, KAMINSKI M, et al. Long-term efficacy and safely of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myelomaor breast carcinoma: a randomized, double-blind, multicenter, comparative trial[ J]. Cancer, 2003,98 ( 8 ) : 1735 - 1744.
  • 5McClung MR, San Martin J, et al.Opposite bone remodel- ing effects of teriparatide and alendronate in increasing bone mass[J].Arcb Int Meal,2005,165: 1762-1768.
  • 6Widler L, Jaeggi KA, GlattM, et al. Highly potent geminal bisphospnonates. From pamidronate disodium (Aredia) to zoledronicacid (Zometa) [ J ] .J Med Chem, 2002, 45 (17): 3721-3738.
  • 7Van den WT, HuizingMT, Vermorken JB. Bisphosphonates and osteonecrosis of the jaw : cause and effect or a post hoc faffacy [ J]. Ann Oncol, 2006, 17 (8): 1197-1204.
  • 8Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing ep idem- ic [ J ].OralMaxillofac Surg, 2003, 61 (9): 1115-1117.
  • 9Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates[J].N Engl J Med, 2005, 353: 99-102.
  • 10DimopoulosMA, Kastritis E, Anagnostopoulos A, et al. Os- teonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid [J].Haematologica, 2006, 91 (7) : 968-971.

共引文献22

同被引文献88

引证文献7

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部